Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dryland Genetics is an agricultural biotechnology company focused on developing high-yielding, water-efficient crops for arid and semi-arid environments. The company utilizes a proprietary genomic selection platform to accelerate the breeding of proso millet, a grain that requires significantly less water than corn or sorghum. By improving the productivity of crops that thrive on marginal land, Dryland Genetics aims to enhance food security and provide sustainable options for farmers facing water scarcity. Their lead products include improved proso millet varieties, such as D3 and D4, which have demonstrated substantial yield increases over traditional cultivars. The company's technology allows for the development of new crop varieties in a fraction of the time required by traditional breeding methods. Headquartered in Ames, Iowa, Dryland Genetics serves the agricultural needs of the Great Plains and other water-stressed regions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dryland Genetics.